Matinas BioPharma Holdings Inc (MTNB) — Cash Flow-to-Debt Ratio
Matinas BioPharma Holdings Inc (MTNB) has a Cash Flow-to-Debt Ratio of -0.56x as of March 2026, meaning its operating cash flow of $-1.60 Million could theoretically repay -1% of its total liabilities ($2.85 Million) in one year. See how financially flexible is Matinas BioPharma Holdings Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Matinas BioPharma Holdings Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Matinas BioPharma Holdings Inc across 14 annual periods. For the full cash flow conversion analysis, see Matinas BioPharma Holdings Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Matinas BioPharma Holdings Inc (2012–2025)
Year-by-year debt coverage analysis for Matinas BioPharma Holdings Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.95x | $-7.01 Million | $2.38 Million | ▲ +6.3% |
| 2024 | -3.14x | $-15.88 Million | $5.05 Million | ▼ -20.6% |
| 2023 | -2.61x | $-15.28 Million | $5.86 Million | ▼ -474.9% |
| 2022 | -0.45x | $-19.16 Million | $42.23 Million | ▲ +73.7% |
| 2021 | -1.72x | $-15.22 Million | $8.83 Million | ▲ +28.2% |
| 2020 | -2.40x | $-17.37 Million | $7.24 Million | ▼ -22.4% |
| 2019 | -1.96x | $-14.09 Million | $7.19 Million | ▲ +27.8% |
| 2018 | -2.72x | $-10.32 Million | $3.80 Million | ▲ +11.3% |
| 2017 | -3.06x | $-11.46 Million | $3.74 Million | ▼ -33.5% |
| 2016 | -2.29x | $-6.12 Million | $2.67 Million | ▲ +31.5% |
| 2015 | -3.35x | $-7.81 Million | $2.33 Million | ▲ +52.3% |
| 2014 | -7.02x | $-7.96 Million | $1.13 Million | ▼ -101.9% |
| 2013 | -3.48x | $-2.99 Million | $858.97K | ▼ -412.8% |
| 2012 | -0.68x | $-57.26K | $84.43K | — |